Waeber B, Brunner H R
Schweiz Med Wochenschr. 1982 Sep 25;112(39):1330-4.
Today two largely new approaches are available for the treatment of clinical hypertension. First, captopril, an orally active angiotensin converting enzyme inhibitor, makes possible chronic blockade of the renin-angiotensin system. This compound, given alone or in combination with a diuretic, normalizes the blood pressure of most hypertensive patients. Unfortunately, because captopril may induce serious adverse effects the use of this inhibitor must be restricted to patients with high blood pressure refractory to conventional antihypertensive drugs. Second, compounds such as verapamil and nifedipine are capable of producing a marked vasodilating effect by inhibiting the entry of calcium into the vascular smooth muscle cells. However, the role of calcium channel blockers in the treatment of hypertensive disease awaits more precise definition.
如今，有两种在很大程度上全新的方法可用于治疗临床高血压。首先，卡托普利是一种口服活性血管紧张素转换酶抑制剂，它使得对肾素 - 血管紧张素系统的长期阻断成为可能。这种化合物单独使用或与利尿剂联合使用，可使大多数高血压患者的血压恢复正常。不幸的是，由于卡托普利可能会引发严重的不良反应，这种抑制剂的使用必须仅限于对传统抗高血压药物难治的高血压患者。其次，诸如维拉帕米和硝苯地平之类的化合物能够通过抑制钙进入血管平滑肌细胞而产生显著的血管舒张作用。然而，钙通道阻滞剂在高血压疾病治疗中的作用尚待更精确的界定。
